Mabvax Therapeutics Holdings Inc., of San Diego, said it closed its securities purchase agreements with investors providing for the registered sale of approximately $1.31 million of shares of series J convertible preferred stock, representing approximately 2,386.36 shares at a purchase price of $550 per share.